Ovarian Cancer - KOL Insight

Readouts of AstraZeneca's DUO-O positive study demonstrated significantly improved progression free survival - so why do KOLs doubt it will be practice changing? Experts are excited by the potential of ImmunoGen's ADC Elahere, but what safety concerns could impact its uptake? What factors underpin the prescribing of AstraZeneca/Merck & Co's Lynparza and GSK's Zejula PARP inhibitors? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (5)

Current and future treatment algorithm

Research objectives (2)

Marketed products (28)

• PARPis (14)
  • Insights for the PARPis (Lynparza, Rubraca, Zejula) (3)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (1)
  • Rubraca (rucaparib; Clovis Oncology) (1)
  • Zejula (niraparib; GSK) (9)
• ADC/tubulin inhibitors (14)
  • Insights for the ADC/tubulin inhibitor (3)
  • Elahere (mirvetuximab soravtansine; ImmunoGen) (11)

Pipeline products (78)

• Immune checkpoint inhibitors (ICI) (15)
  • Insights for the ICI class (3)
  • Bavencio (avelumab; Merck Group) (1)
  • Imfinzi (durvalumab; AstraZeneca) (1)
  • Jemperli (dostarlimab; GSK) (1)
  • Keytruda (pembrolizumab; Merck & Co.) (1)
  • Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono) (1)
  • Tecentriq (atezolizumab; Roche) (7)
• Therapeutic vaccines (22)
  • Oregovomab (anti-idiotype mAb; OncoQuest) (10)
  • Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation) (6)
  • Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis) (6)
• Other late-stage modalities (14)
  • UpRi (upifitamab rilsodotin; Adimab/Mersana Therapeutics) (7)
  • Batiraxcept (GAS6-AXL pathway inhibitor; Aravive) (7)
• Glucocorticoid receptor antagonists (11)
  • Korlym (relacorilant; Corcept Therapeutics) (7)
  • Tumour treating fields (TTFs; Novocure) (4)
• Mid and early-stage modalities (16)
  • Next-generation ADCs and other MOAs (2)
  • AZD 1775/MK 1775 (adavosertib; Merck & Co/AstraZeneca) (1)
  • AZD 8205 (AstraZeneca) (1)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo) (1)
  • IMGN 151 (ImmunoGen) (1)
  • MK-4830 (Merck & Co) (1)
  • REGN 4018 (ubamatamab; Regeneron) (1)
  • SKB 264/MK-2870 (Merck & Co) (1)
  • STRO-002 (luveltamab tazevibulin; Sutro Biopharma) (1)
  • VS-6766 (avutometinib; Verastem Oncology) (6)

Appendix (4)

• KOL details (4)
  • KOLs from the US (1)
  • KOLs from Europe (2)